Luteolin, a bioflavonoid inhibits azoxymethane-induced colon carcinogenesis: Involvement of iNOS and COX-2
Open Access
- 1 January 2014
- journal article
- research article
- Published by SAGE Publications in Pharmacognosy Magazine
- Vol. 10 (38) , 306-10
Abstract
Colon cancer (CRC) is a serious health problem through worldwide. Development of novel drug without side effect for this cancer was crucial. Luteolin (LUT), a bioflavonoid has many beneficial effects such as antioxidant, anti-inflammatory, anti-proliferative properties. Azoxymethane (AOM), a derivative of 1, 2-Dimethyl hydrazine (DMH) was used for the induction of CRC in Balb/C mice. CRC was induced by intraperitoneal injection of AOM to mice at the dose of 15 mg/body kg weight for 3 weeks. Mouse was treated with LUT at the dose of 1.2 mg/body kg weight orally until end of the experiment. The expression of inducible nitric oxide synthase (iNOS) and cyclooxygense (COX)-2 were analyzed by RT-PCR and immunohistochemistry. The expressions of iNOS and COX-2 were increased in the case of AOM induction. Administration of LUT effectively reduced the expressions of iNOS and COX-2. The present study revealed that, LUT suppresses both iNOS and COX-2 expressions and act as an anti-inflammatory role against CRC.Keywords
This publication has 42 references indexed in Scilit:
- Luteolin inhibits cell proliferation during Azoxymethane-induced experimental colon carcinogenesis via Wnt/ β-catenin pathwayInvestigational New Drugs, 2009
- Luteolin suppresses inflammation-associated gene expression by blocking NF-κB and AP-1 activation pathway in mouse alveolar macrophagesLife Sciences, 2007
- Evaluation of the Anti-inflammatory Activity of Luteolin in Experimental Animal ModelsPlanta Medica, 2007
- Chemoprevention of CancerCA: A Cancer Journal for Clinicians, 2004
- Studies with the azoxymethane–rat preclinical model for assessing colon tumor development and chemopreventionEnvironmental and Molecular Mutagenesis, 2004
- DIETARY FLAVONOIDS: Bioavailability, Metabolic Effects, and SafetyAnnual Review of Nutrition, 2002
- Cyclooxygenase-2: A Therapeutic TargetAnnual Review of Medicine, 2002
- Growth Inhibitory Effects of Flavonoids in Human Thyroid Cancer Cell LinesThyroid®, 1999
- Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2Cell, 1995
- Growth inhibitory effects of bioflavonoids and related compounds on human leukemic CEM-C1 and CEM-C7 cellsCancer Letters, 1992